Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies

Details for Australian Patent Application No. 2009327374 (hide)

Owner Anthera Pharmaceuticals, Inc.

Inventors Hislop, Colin; Trias, Joaquim; Odink, Debra; Truex, Paul

Agent Spruson & Ferguson

Pub. Number AU-A-2009327374

PCT Pub. Number WO2010/071854

Priority 61/174,423 30.04.09 US; 61/139,400 19.12.08 US; 61/239,967 04.09.09 US

Filing date 18 December 2009

Wipo publication date 24 June 2010

International Classifications

A01N 43/38 (2006.01) Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

7 July 2011 PCT application entered the National Phase

  PCT publication WO2010/071854 Priority application(s): WO2010/071854

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009327376-Method and apparatus for storage and/ or introduction of implant for hollow anatomical structure

2009327373-Thiazolopyridine sirtuin modulating compounds